tiprankstipranks
Community Health (CYH)
NYSE:CYH
Want to see CYH full AI Analyst Report?

Community Health (CYH) AI Stock Analysis

428 Followers

Top Page

CYH

Community Health

(NYSE:CYH)

Select Model
Select Model
Select Model
Neutral 42 (OpenAI - 5.2)
Rating:42Neutral
Price Target:
$2.50
▼(-8.42% Downside)
Action:Reiterated
Date:07/24/26
The score is held down primarily by fragile financial performance (negative equity, high leverage, and weak/declining TTM revenue and free cash flow). The latest earnings call adds pressure due to a guidance cut and payer-mix/cash-collection headwinds. Technicals also reflect a sustained downtrend, while valuation is not compelling given a negative P/E and no dividend yield provided.
Positive Factors
Same-store volume growth
Sustained same-store revenue and admissions growth indicates underlying demand strength in core non-urban markets. Over 2-6 months this supports revenue stability and utilization-driven margin recovery, making organic growth a durable source of performance as divestitures pare non-core assets.
Negative Factors
High leverage & negative equity
Persistently negative equity and multi-billion dollar debt create structural financial fragility. High leverage limits strategic optionality, heightens refinancing risk if cash flow softens, and constrains capital allocation for investments or margin-improving initiatives over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Same-store volume growth
Sustained same-store revenue and admissions growth indicates underlying demand strength in core non-urban markets. Over 2-6 months this supports revenue stability and utilization-driven margin recovery, making organic growth a durable source of performance as divestitures pare non-core assets.
Read all positive factors

Community Health Key Performance Indicators (KPIs)

Any
Any
Revenue by Source
Revenue by Source
Breaks down where the company earns money—Medicare, Medicaid, commercial insurers, self-pay, and services like outpatient or ancillary care. A heavy reliance on lower-paying government programs or one dominant payer raises reimbursement and policy risk, while a diversified mix with higher-margin services supports revenue stability and profit potential.
Chart InsightsThe revenue mix has shifted toward government payors: a reporting-driven emergence of Medicare Managed Care (which explains the late‑2022 drop in the broad Managed Care category) plus a steady rise in Medicaid share, while traditional Medicare has declined. That secular shift toward lower‑margin government and growing self‑pay volumes helps explain falling revenue per admission and margin pressure; it clarifies why management is leaning on state‑directed payment wins and aggressive cost controls to sustain EBITDA.
Data provided by:The Fly

Community Health (CYH) vs. SPDR S&P 500 ETF (SPY)

Community Health Business Overview & Revenue Model

Company Description
Community Health Systems, Inc. (CYH) operates as a major healthcare provider across the United States, focusing on the ownership, leasing, and management of general acute care hospitals. The organization offers a comprehensive array of medical ser...
How the Company Makes Money
CYH generates revenue primarily by providing healthcare services through its hospitals and outpatient operations and billing payers for those services. The largest revenue stream is patient service revenue: payments received from commercial insure...

Community Health Earnings Call Summary

Earnings Call Date:Jul 22, 2026
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Oct 28, 2026
Earnings Call Sentiment Negative
The call reflected meaningful operational and clinical progress (quality recognitions, improved employee engagement, same-store volume gains, cost controls, procurement improvements, and beneficial state-directed payment recognition). However, these positives were outweighed by material financial headwinds: a 9.8% decline in net revenue, lower Adjusted EBITDA ($330M vs $380M), softness in elective surgeries and unfavorable payer mix with rising uninsured/self-pay volumes, pre-payment audit-driven AR/cash timing pressure, and a reduction in full-year Adjusted EBITDA guidance. Management has taken balance-sheet actions and sees improving exit trends, but near-term demand and payer-mix challenges drove a cautious outlook.
Positive Updates
Quality and Clinical Improvements
Notable progress on quality metrics: 12 hospitals achieved Leapfrog A grades and ~70% of hospitals achieved Leapfrog A or B; Lutheran Hospital received the American College of Cardiology HeartCARE Distinction (one of ~100 nationally); multiple hospitals recognized by CMS for zero hospital-acquired infections; record achievements in risk-adjusted mortality index, sepsis mortality, and HAI rates; improvements in patient experience, physician experience, and employee engagement (record employee survey response rates).
Negative Updates
Significant Year-over-Year Revenue and EBITDA Declines
Net revenue declined 9.8% year-over-year; Adjusted EBITDA fell to $330 million from $380 million (a decline of ~$50M) and margin declined to 11.7% from 12.1% in the prior year period.
Read all updates
Q2-2026 Updates
Negative
Quality and Clinical Improvements
Notable progress on quality metrics: 12 hospitals achieved Leapfrog A grades and ~70% of hospitals achieved Leapfrog A or B; Lutheran Hospital received the American College of Cardiology HeartCARE Distinction (one of ~100 nationally); multiple hospitals recognized by CMS for zero hospital-acquired infections; record achievements in risk-adjusted mortality index, sepsis mortality, and HAI rates; improvements in patient experience, physician experience, and employee engagement (record employee survey response rates).
Read all positive updates
Company Guidance
Management updated 2026 guidance to net revenue of $11.4–$11.6 billion and Adjusted EBITDA of $1.30–$1.375 billion (down from an initial midpoint of $1.415 billion after a ~$60–$70 million reduction tied to H1 results and similar assumed H2 weakness); Q2 Adjusted EBITDA was $330 million (11.7% margin vs 12.1% prior year) on a reported 9.8% decline in net revenue while same‑store net revenue rose 2.4%, same‑store adjusted admissions increased 2.9% (inpatient +1.9%), and same‑store net revenue per adjusted admission fell 0.5%. The company attributes the revision to exchange disenrollment/self‑pay pressure (initially modeled as $90–$110 million net revenue and $20–$30 million EBITDA impact; Q1 ~ $25M and Q2 ~ $20M EBITDA hits, now implying roughly $50–$75M of annual EBITDA headwind), partially offset by $40–$45 million of combined Q2 EBITDA from approved Florida and Indiana state‑directed payment programs (about $20–$25M of which related to prior periods and partly offset by an approximate $15M reduction in Arizona). Cash from operations was $87M in Q2 ($143M adjusted for divestiture tax timing), the company repurchased ~$368M of 4.75% 2031 notes and ~$231M of 10.875% 2032 notes, ended the quarter at 6.7x leverage (6.6x YE2025) with no ABL drawn, and expects DPP benefits from Georgia, Indiana and potentially Florida to affect full‑year results.

Community Health Financial Statement Overview

Summary
Weak financial quality driven by a highly leveraged balance sheet with persistent negative equity, plus deteriorating TTM revenue and negative TTM free cash flow. While there are periods of decent EBITDA margins and positive operating cash flow (notably 2025), recent softness and inconsistent cash generation increase refinancing and funding risk.
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
27
Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue22.41B12.48B12.63B12.49B12.21B12.37B
Gross Profit13.02B1.08B5.27B5.08B4.91B5.08B
EBITDA4.91B2.02B1.25B1.29B1.17B1.71B
Net Income-300.00M509.00M-516.00M-133.00M46.00M230.00M
Balance Sheet
Total Assets12.18B13.20B14.05B14.46B14.67B15.22B
Cash, Cash Equivalents and Short-Term Investments149.00M260.00M37.00M38.00M118.00M507.00M
Total Debt10.21B11.58B12.10B12.17B12.39B12.82B
Total Liabilities13.34B14.04B15.37B15.28B15.40B16.03B
Stockholders Equity-1.39B-1.39B-1.91B-1.39B-1.37B-1.37B
Cash Flow
Free Cash Flow-185.00M208.00M120.00M-257.00M-115.00M-600.00M
Operating Cash Flow126.00M543.00M480.00M210.00M300.00M-131.00M
Investing Cash Flow1.06B847.00M-277.00M-22.00M-251.00M-543.00M
Financing Cash Flow-1.49B-1.17B-204.00M-268.00M-438.00M-495.00M

Community Health Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.73
Price Trends
50DMA
3.11
Negative
100DMA
3.01
Negative
200DMA
3.18
Negative
Market Momentum
MACD
-0.07
Negative
RSI
48.41
Neutral
STOCH
58.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYH, the sentiment is Neutral. The current price of 2.73 is below the 20-day moving average (MA) of 2.93, below the 50-day MA of 3.11, and below the 200-day MA of 3.18, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 48.41 is Neutral, neither overbought nor oversold. The STOCH value of 58.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CYH.

Community Health Risk Analysis

Community Health disclosed 37 risk factors in its most recent earnings report. Community Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Community Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
83
Outperform
$2.20B20.709.57%15.88%25.01%
72
Outperform
$12.31B19.8623.14%0.67%9.47%19.85%
72
Outperform
$3.47B24.3512.94%1.15%7.19%32.91%
69
Neutral
$1.97B8.51241.47%19.52%1337.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
42
Neutral
$410.34M-1.3120.91%-5.25%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CYH
Community Health
2.97
0.24
8.79%
ADUS
Addus Homecare
117.59
3.73
3.28%
EHC
Encompass Health
123.55
4.75
4.00%
NHC
National Healthcare
219.84
115.29
110.27%
AVAH
Aveanna Healthcare Holdings
11.29
4.09
56.81%

Community Health Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A Transactions
Community Health Systems Reports Lower Q2 2026 Results
Negative
Jul 22, 2026
For the quarter ended June 30, 2026, Community Health Systems reported net operating revenues of $2.825 billion, down 9.8% from a year earlier, with same-store revenues up 2.4% as divestitures weighed on consolidated results. Quarterly net income ...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance
Community Health finalizes major Arkansas hospital asset sale
Negative
Jun 1, 2026
On June 1, 2026, Community Health Systems completed the previously announced sale of substantially all assets and certain liabilities tied to four Northwest Arkansas hospitals and associated outpatient centers to Freeman Health System for $110 mil...
Executive/Board ChangesShareholder Meetings
Community Health Shareholders Reaffirm Board, Leadership and Governance
Positive
May 13, 2026
At its annual meeting of stockholders held on May 12, 2026, Community Health Systems, Inc. shareholders elected all 14 director nominees, including Chief Executive Officer Kevin J. Hammons and Executive Chairman Wayne T. Smith, to terms expiring a...
Business Operations and StrategyPrivate Placements and Financing
Community Health announces successful $600 million debt tender
Positive
May 6, 2026
On May 6, 2026, Community Health Systems announced early tender results for a previously launched cash tender offer of up to $600 million to repurchase portions of its 4.750% senior secured notes due 2031 and 10.875% senior secured notes due 2032....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2026